|
- Pojem -
|
- Vysvětlení -
|
|
Vepesid
|
Etoposid
|
|
OS (Overall Survival)
|
Defined as the time from randomization (or treatment initiation in single-arm studies) to death from any cause.
|
|
DFS (Disease-Free Survival)
|
Time from randomization to disease recurrence or death, used primarily in adjuvant (post-surgical/radiation) settings.
|
|
PFS (Progression-Free Survival)
|
Time from randomization to documented tumor progression or death, often used in advanced/metastatic settings.
|
|
ORR (Objective Response Rate)
|
The proportion of patients achieving tumor shrinkage (CR or PR) per standardized criteria (e.g., RECIST 1.1 for solid tumors).
|
|
CR (Complete Response)
|
Disappearance of all target lesions and normalization of tumor markers for a minimum duration (usually ≥4 weeks).
|
|
PR (Partial Response)
|
≥30% reduction in the sum of diameters of target lesions, maintained for at least 4 weeks.
|
|
SD (Stable Disease)
|
Insufficient shrinkage for PR and insufficient increase for PD.
|
|
PD (Progressive Disease)
|
≥20% increase in the sum of target lesion diameters or appearance of new lesions.
|
|
DCR (Disease Control Rate)
|
Proportion of patients with CR, PR, or SD maintained beyond a minimum duration.
|
cDDP
LiFraumeni
Ki67
SSME
SNBL
AE SSE-FIM
NACHT 4AC
infliximab
ovosan
Lynparza
Lymfoscintigrafie
capecitabin
Keytruda
Fulvestrant
Tamoxifen